Drug news

Combination Vfend plus Eraxis fails Phase III trial for Aspergillosis

Read time: 1 mins

Last updated:2nd Oct 2011

Published:2nd Oct 2011

Source: Pharmawand

A Phase III trial has failed to show a statistically significant benefit in combining antifungal medications, Vfend (voriconazole) plus Eraxis/Ecalta (anidulafungin) both drugs from Pfizer compared with using Vfend alone in treating invasive aspergillosis. Vfend now has generic competition in the USA

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news